
Opinion|Videos|December 12, 2025
Clinical Considerations for Erythrocyte-stimulating Agents and Luspatercept
Author(s)Caleb J. Scheckel, DO , Clark Alsfeld, MD
Explore the clinical considerations for choosing between ESAs and luspatercept in treating low-risk MDS, focusing on efficacy and patient convenience.
Advertisement
Episodes in this series

When choosing between ESAs and luspatercept as first-line therapy in low-risk MDS, clinicians typically weigh disease biology, patient characteristics, and predictors of response. Additional factors—such as transfusion burden, comorbidities, and patient preferences—also shape the decision. While combination therapy is an emerging area of interest, current data remain limited, and the approach is not yet standard practice. Ongoing studies may clarify whether sequential or combined use can optimize durability of response and reduce transfusion dependence.
Advertisement
Related to this article

Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.

Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.

The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.

Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.

The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
4
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
5

